Stocks in play: Revive Therapeutics Ltd

Provides an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. Revive Therapeutics Ltd shares C.RVV are trading up $0.05 at $0.43.